The effect of IFN-β on CREB3L1 nuclear translocation when used with DOX may also have a clinical application by predicting more sustained responses to DOX in EOC patients because activation of the IFN-β/IFNAR/IRF7 signaling axis have been reported to instigate immunological dormancy in some chemotherapy-treated cancers,40 and the role of type I IFN in promoting response to chemotherapy in tumor cells has been recently reported.10 Here, IRF7 is linked to neoplasm.